Skip to main content
ModernaPatent grant

Moderna was granted a patent for a genetic treatment for cystic fibrosis.

Source: Autobound Signal API · 106 signals tracked for Moderna · updated

Get Moderna's live signals in Claude or ChatGPT, or by API

AskWhat changed at Moderna this week? Use Autobound signals for modernatx.com.

What happened

In October 2026 Moderna patented nucleic-acid delivery technology designed to restore CFTR activity in people with cystic fibrosis, potentially through in-body treatment.

Source

Abstract

This disclosure relates to delivery vehicles comprising payload molecules, e.g., mRNA or gene editing therapeutics for the treatment of cystic fibrosis (CF). Nucleic acid therapeutics (e.g., mRNAs) for use in the invention, when administered in vivo, encode cystic fibrosis transmembrane conductance regulator (CFTR). Nucleic acid therapeutics (e.g., mRNAs) of the disclosure increase and/or restore deficient levels of CFTR expression and/or activity in subjects. Nucleic acid therapeutics (e.g., mRNAs) of the disclosure further decrease abnormal accumulation of ammonia associated with deficient CFTR activity in subjects.

patents.google.com/patent/US12774310Read the full source

Extracted by Autobound

From the Signal API record
Signal
Patent grant

What this signalsA new patent often shows where a company is putting its R&D budget.

Grant date
Oct 27, 2026
Inventors
4
Patent number
US12774310
Assignee
ModernaTX, Inc.

The full record

From the Signal API record

People

  • Jean C. SungInventor
  • David ReidInventor
  • Alicia Anne BicknellInventor
  • Ana Cadete PiresInventor
  • Jeffrey HrkachInventor

Details

Primary CPC class
C07K 14/4712
USPTO assignee
ModernaTX, Inc.
What the invention does
A delivery system that brings mRNA or gene-editing instructions into cells so they can produce more working CFTR protein.

Topics and mentions

Tags

  • Intellectual Property
  • Research & Development
  • Bioengineering
  • Medical Research
  • Pharmaceuticals

Technologies named

  • mRNA therapeutics
  • gene editing
  • nucleic acid delivery
  • CFTR

Extraction

Detected
Oct 30, 2026
signal_type
patents-company
signal_subtype
patentGrant

Use this data

Get every patent signal for Moderna and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Moderna this week?”

  2. Send it to your own tools

    The Signal API returns patent signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full patents-company record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/86c51112-aa02-528a-9064-b26dcf29e3f6 returns this record as JSON. POST /v1/companies/enrich returns every signal for modernatx.com.

{
  "signal_id": "86c51112-aa02-528a-9064-b26dcf29e3f6",
  "signal_type": "patents-company",
  "signal_subtype": "patentGrant",
  "detected_at": "2026-10-30T00:09:00+00:00",
  "company": {
    "name": "Moderna",
    "domain": "modernatx.com"
  },
  "data": {
    "cpc": [
      {
        "code": "C07K 14/4712"
      },
      {
        "code": "A61K 47/10"
      },
      {
        "code": "A61K 47/6909"
      },
      {
        "code": "A61P 11/00"
      }
    ],
    "tags": [
      "Intellectual Property",
      "Research & Development",
      "Bioengineering",
      "Medical Research",
      "Pharmaceuticals"
    ],
    "detail": "In October 2026 Moderna patented nucleic-acid delivery technology designed to restore CFTR activity in people with cystic fibrosis, potentially through in-body treatment.",
    "summary": "Moderna was granted a patent for a genetic treatment for cystic fibrosis.",
    "event_at": "2026-10-27",
    "inventors": [
      {
        "name": "Jean C. Sung",
        "status": "unresolved",
        "is_primary": true
      },
      {
        "name": "David Reid",
        "status": "resolved",
        "is_primary": false,
        "linkedin_url": "https://www.linkedin.com/in/david-reid-b7620538"
      },
      {
        "name": "Alicia Anne Bicknell",
        "status": "resolved",
        "is_primary": false,
        "linkedin_url": "https://www.linkedin.com/in/alicia-bicknell"
      },
      {
        "name": "Ana Cadete Pires",
        "status": "resolved",
        "is_primary": false,
        "linkedin_url": "https://www.linkedin.com/in/acadetepires"
      },
      {
        "name": "Jeffrey Hrkach",
        "status": "unresolved",
        "is_primary": false
      }
    ],
    "event_kind": "grant_date",
    "grant_date": "2026-10-27",
    "source_url": "https://patents.google.com/patent/US12774310",
    "cpc_primary": {
      "code": "C07K 14/4712"
    },
    "patent_title": "Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis",
    "patent_number": "US12774310",
    "uspto_assignee": "ModernaTX, Inc.",
    "patent_abstract": "This disclosure relates to delivery vehicles comprising payload molecules, e.g., mRNA or gene editing therapeutics for the treatment of cystic fibrosis (CF). Nucleic acid therapeutics (e.g., mRNAs) for use in the invention, when administered in vivo, encode cystic fibrosis transmembrane conductance regulator (CFTR). Nucleic acid therapeutics (e.g., mRNAs) of the disclosure increase and/or restore deficient levels of CFTR expression and/or activity in subjects. Nucleic acid therapeutics (e.g., mRNAs) of the disclosure further decrease abnormal accumulation of ammonia associated with deficient CFTR activity in subjects.",
    "precision_class": "structural",
    "invention_explanation": "A delivery system that brings mRNA or gene-editing instructions into cells so they can produce more working CFTR protein.",
    "technologies_mentioned": [
      "mRNA therapeutics",
      "gene editing",
      "nucleic acid delivery",
      "CFTR"
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.